329 related articles for article (PubMed ID: 34109764)
21. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
Moreira FL; Melli PPDS; Marques MP; Rocha A; Nardotto GHB; Duarte G; Lanchote VL
J Clin Pharmacol; 2023 Feb; 63(2):219-227. PubMed ID: 36087110
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
Trivedi A; Sohn W; Kulkarni P; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Wahlstrom J; Lee E; Dutta S
Clin Transl Sci; 2021 Nov; 14(6):2510-2520. PubMed ID: 34415673
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate.
Mohamed MF; Minocha M; Trueman S; Feng T; Enejosa J; Fisniku O; Othman AA
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):299-306. PubMed ID: 32648334
[TBL] [Abstract][Full Text] [Related]
24. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
Anderson K; Nelson CH; Gong Q; Alani M; Tarnowski T; Othman AA
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):235-245. PubMed ID: 34468080
[TBL] [Abstract][Full Text] [Related]
27. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
Choi H; Huang F; Flack M
Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990
[TBL] [Abstract][Full Text] [Related]
28. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
Nebot N; Won CS; Moreno V; Muñoz-Couselo E; Lee DY; Gasal E; Bouillaud E
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1054-1063. PubMed ID: 33932130
[TBL] [Abstract][Full Text] [Related]
31. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
[TBL] [Abstract][Full Text] [Related]
32. Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.
Ho YL; Gorycki P; Ferron-Brady G; Martin P; Vlasakakis G
Clin Transl Sci; 2024 Apr; 17(4):e13799. PubMed ID: 38634429
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Tarkiainen EK; Neuvonen M; Holmberg M; Kiiski JI; Lapatto-Reiniluoto O; Filppula AM; Kurkela M; Backman JT; Niemi M
Clin Pharmacol Ther; 2024 Jan; 115(1):71-79. PubMed ID: 37786998
[TBL] [Abstract][Full Text] [Related]
34. The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
Mohamed MF; Trueman S; Feng T; Friedman A; Othman AA
J Clin Pharmacol; 2019 Apr; 59(4):510-516. PubMed ID: 30500075
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
[TBL] [Abstract][Full Text] [Related]
36. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
[TBL] [Abstract][Full Text] [Related]
37. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
38. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.
Wu HF; Hristeva N; Chang J; Liang X; Li R; Frassetto L; Benet LZ
J Pharm Sci; 2017 Sep; 106(9):2751-2757. PubMed ID: 28385543
[TBL] [Abstract][Full Text] [Related]
39. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
